In standard experimental environments, a constant proportion of CA1 principal cells are place cells, each with a spatial receptive field called a place field. Although the properties of place cells are a basis for understanding the mammalian representation of spatial knowledge, there is no consensus on which of the two fundamental neural-coding hypotheses correctly accounts for how place cells encode spatial information. Within the dedicated-coding hypothesis, the current activity of each cell is an independent estimate of the location with respect to its place field. The average of the location estimates from many cells represents current location, so a dedicated place code would degrade if single cells had multiple place fields. Within the alternative, ensemble-coding hypothesis, the concurrent discharge of many place cells is a vector that represents current location. An ensemble place code is not degraded if single cells have multiple place fields as long as the discharge vector at each location is unique. Place cells with multiple place fields might be required to represent the substantially larger space in more natural environments. To distinguish between the dedicated-coding and ensemblecoding hypotheses, we compared the characteristics of CA1 place fields in a standard cylinder and an approximately six times larger chamber. Compared with the cylinder, in the chamber, more CA1 neurons were place cells, each with multiple, irregularly arranged, and enlarged place fields. The results indicate that multiple place fields is a fundamental feature of CA1 place cell activity and that, consequently, an ensemble place code is required for CA1 discharge to accurately signal location.

No abstract

No abstract

SUMMARYPurpose: To determine whether muscimol delivered epidurally or into the subarachnoid space can prevent and/or terminate acetylcholine (Ach)-induced focal neocortical seizures at concentrations not affecting behavior and background electroencephalography (EEG) activity. Methods: Rats (n = 12) and squirrel monkeys (n = 3) were chronically implanted with an epidural or subarachnoid drug delivery device, respectively, over the right frontal/parietal cortex, with adjacent EEG electrodes. Recordings were performed in behaving rats and chaired monkeys. Via the implants, either a control solution (artificial cerebrospinal fluid, ACSF) or muscimol (0.25-12.5 mm) was delivered locally as a ''pretreatment,'' followed by the similar delivery of a seizure-inducing concentration of Ach. In five additional rats, the quantities of food-pellets consumed during epidural ACSF and muscimol (2.5 mm) exposures were measured. In a last group of four rats, muscimol (0.8-2.5 mm) was delivered epidurally during the ongoing, Achinduced EEG seizure. Results: In contrast to ACSF pretreatments, epidural muscimol pretreatment in rats completely prevented the seizures at and above 2.5 mm. In the monkeys, subarachnoid muscimol pretreatments at 2.5 mm completely prevented the focal-seizure-inducing effect of Ach, whereas similar deliveries of ACSF did not affect the seizures. Furthermore, 2.5 mm epidural muscimol left the eating behavior of rats intact and caused only slight changes in the EEG power spectra. Finally, muscimol delivery during Ach-induced EEG seizures terminated the seizure activity within 1-3 min. Conclusions: The results of this study suggest that muscimol is a viable candidate for the transmeningeal pharmacotherapy of intractable focal epilepsy.